Here are the S-3 shelf registrations from Celcuity Inc. (CELC) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow CELC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CELC filings page.
Celcuity Inc. has filed an automatic shelf registration statement, including a sales agreement prospectus to offer up to $400,000,000 of its common stock from time to time through an at-the-market program with Jefferies. The shelf also registers an indeterminate amount of common stock, preferred stock, warrants, debt securities and units, which may be issued in multiple offerings using various distribution methods.
Celcuity is a clinical-stage biotechnology company developing targeted therapies for solid tumors, led by gedatolisib, a PI3K/AKT/mTOR pathway inhibitor in multiple Phase 3 and earlier-stage trials for breast, prostate and endometrial cancers. As a smaller reporting company, it uses scaled disclosure and plans to use any net proceeds primarily for working capital and general corporate purposes, including clinical and commercial activities for gedatolisib.